PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 5 | 4 | A145-150
Article title

Cisplatin-induced cardiotoxicity – two case reports

Content
Title variants
Languages of publication
EN
Abstracts
EN
Cisplatin has been used for over 40 years in various cancer chemotherapies. Toxicity induced by cisplatin-based therapeutic regimens include gastrointestinal toxicity, myelotoxicity, neurotoxicity, ototoxicity and nephrotoxicity. Cisplatin-based regimens have been associated with a wide range of cardiovascular complications. In this paper, we report 2 cases of cisplatin induced cardiotoxicity. We present cases of 2 young patients who developed acute myocardial infarction during combination chemotherapy with bleomycin, etoposide and cisplatin. The first patient had acute anterior wall ST elevation myocardial infarction and the second one had acute myocardial infarction with peripheral arterial thromboembolism. Cisplatin use can result in cardiovascular events. Clinicians should be very cautious while managing patients on cisplatin-based chemotherapy. Early recognition of cardiotoxicity will allow for timely prevention of permanent cardiac damage.
Discipline
Publisher
Journal
Year
Volume
5
Issue
4
Pages
A145-150
Physical description
References
  • 1. Rosenberg B. Platinum complexes for the treatment of cancer. Interdiscipl Sci Rev 1978; 3: 134-147.
  • 2. Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205: 698.
  • 3. Reed E. Cisplatin, Carboplatin and Oxaliplatin. In: Chabner BA, Longo DL (ed.). Cancer chemotherapy and biotherapy – principles and practice. Lippincott Williams & Wilkins, Philadelphia 2006: 332.
  • 4. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4: 307-320.
  • 5. El-Awady el-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335-341.
  • 6. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
  • 7. Patanè S. Cardiotoxicity: cisplatin and long term cancer survivors. Int J Cardiol 2014; 175(1): 201-202.
  • 8. Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA et al. Propionyl-L-carnitine prevents the progression of cisplatin induced cardiomyopathy in a carnitine- depleted rat model. Pharmacol Res 2006; 53: 278-286.
  • 9. Schimmel KJ, Richel DJ, van den Brink RB et al. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 2004; 30(2): 181-191.
  • 10. Sen F, Karavelioglu Y, Yildiz I et al. Multiple arterial occlusions precipitated by platinum based chemotherapy in a patient with testicular seminoma. Journal-CVS 2014; 2(1): 10-12.
  • 11. Moore R, Adel N, Riedel E et al. High Incidence of Thromboembolic Events in patients treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis. J Clin Oncol 2011; 29: 3466-3473.
  • 12. Martín GG, Fernández SP, Castro VS et al. Vertebral Artery Occlusion after Chemotherapy. Stroke 2008; 39: e38.
  • 13. Tassinari D, Sartori S, Drudi G et al. Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature. Ann Oncol 1997; 8: 1263-1267.
  • 14. Waseem R, Hussain M, Imtiyaz D et al. Cisplatin induced paroxysmal supraventricular tachycardia. Indian J Med Paediatr Oncol 2013; 34(4): 330- -332.
  • 15. Khan S, Chen C, Brady MS et al. Unstable Angina associated With Cisplatin and Carboplatin in a patient With Advanced Melanoma. J Clin Oncol 2012; 30(18): e163-e164.
  • 16. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809-815.
  • 17. Haugnes H, Wethal T, Aass N et al. Cardiovascular Risk Factors and Morbidity in Long-Term survivors of Testicular Cancer: A 20-Year Follow-Up Study. J Clin Oncol 2010; 28(30): 4649-4657.
  • 18. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol 1998; 160: 2021-2024.
  • 19. Shoji S, Miyakita H, Shima M et al. Acute myocardial infarction during combined chemotherapy with bleomycin, etoposide and cisplatin for testicular cancer. Acta Urol 2006; 52: 723-726.
  • 20. Lee YG, Lee E, Kim I et al. Cisplatin based chemotherapy is a strong risk factor for thromboembolic events in small-cell lung cancer. Cancer Res Treat 2015; 47(4): 670-675.
  • 21. Seng S, Liu Z, Chiu SK et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol 2012; 30: 4416-426.
  • 22. Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-9137.
  • 23. Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev 1999; 25: 47-58.
  • 24. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries, relationship to etiology of sudden death ischemic heart disease. Science 1980; 208: 198-200.
  • 25. Dieckmann K, Struss W, Budde U. Evidence for Acute Vascular Toxicity of Cisplatin-based Chemotherapy in Patients with Germ Cell Tumor. Anticancer Research 2011; 31: 4501-4506.
  • 26. Kawano N, Yamaguchi K, Niki T et al. Two cases of acute myocardial infarction during combined chemotherapy in young patients with testicular cancer. J Cardiol Cases 2013; 7: e176-e180.
  • 27. Yang Z, Schumaker LM, Egorin MJ et al. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anionchannel protein in the mitochondrial membrane of head and neck squamous cellcarcinoma: possible role in apoptosis. Clin Cancer Res 2006; 12: 5817-5825.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-30579721-480c-406e-be7b-ef40b5ccb41c
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.